Focus: AllRock Bio is a publicly traded biotechnology company focused on small molecule therapeutics for pulmonary hypertension and other respiratory, oncology, and cardiovascular indications. The company operates as a focused clinical-stage biotech with a lean pipeline centered on ROC-101.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Hot — 32 jobs added in 30d
Net +32 (32 new, 0 removed). Aggressive expansion phase.
AllRock Bio offers equity upside and focused impact potential for those aligned with pulmonary hypertension development, but lack of active hiring and single-asset pipeline pose significant career trajectory and stability concerns.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AllRock Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AllRock Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles